Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (2875)	1/26/2012 11:25:25 AM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3661

Amphastar did not win the appeal, but rather won a stay of the preliminary injunction pending the outcome of the appeal. My take, FWIW: siliconinvestor.com

To: fred hayes who wrote (2875)	6/23/2012 12:46:01 AM
From: tuck	Read Replies (1) \| Respond to of 3661

MNTA off ~20% AH to the low $13s after Teva wins the lower court battle over the Copaxone patents, implying protection for Teva for ~3 years. Obviously, MNTA will appeal, but that process will eat half of the remaining patent life. Still have a small core position. Once we get movement on the generic enoxaparin litigation (court's opinion on why it lifted the injunction -- due any day -- might allow tea leaves to be read on the ultimate outcome), I might add this fall, as I feel that eventually MNTA will get FDA approval for generic Copaxone. Indeed, some were interpreting MNTA's recent strength as anticipation of imminent approval. I am not sure how the market perceives the enoxaparin case, but my guess is low double digits would discount losses on all legal fronts. In any event, with Amphastar's delaying tactics, that case won't resolve until the middle of next year at earliest (a lower court loss by Amphastar might lead to settlement; should MNTA lose & need to appeal, there will not be a settlement). Looking for $11s. So not a buying op at these prices, IMO, not quite yet. Cheers, Tuck